Nexalin Technology Completes Phase 1 of Virtual Clinic
Nexalin Technology, Inc., a pioneer in Deep Intracranial Frequency Stimulation (DIFS) of the brain, has announced the successful completion of Phase 1 of its proprietary virtual clinic. This innovative clinic leverages artificial intelligence (AI) to integrate Electronic Data Capture (EDC) and a Patient Monitoring System (PMS), aiming to revolutionize the clinical trial process and treatment experience for patients.
AI-Driven Clinical Trials and Treatment
The virtual clinic is designed to facilitate the entire clinical trial process virtually, enabling patients to participate from the privacy of their homes. This approach not only enhances patient comfort but also provides physicians with real-time digital data on the patient's treatment experience. The integration of AI into Nexalin's EDC platform and PMS is a significant step forward in managing clinical research capabilities and streamlining the patient experience for its Generation 3 Halo Device.
The Generation 3 Halo Device
Nexalin's Generation 3 Halo Device administers a 15mAmp deep frequency stimulation to the brain, offering a non-invasive treatment option for various mental health conditions, including depression, insomnia, Alzheimer’s disease, and addiction. The device, which requires FDA clearance and a prescription, is designed for home use under the supervision of a licensed physician, supported by an AI-based virtual setting.
Enhancing Patient Care with Technology
The completion of Phase 1 introduces Nexalin's proprietary EDC platform, which enables efficient real-time data acquisition and analysis during clinical trials. Integrated with a patient-friendly smartphone application, the system allows users to initiate treatment sessions virtually, with data automatically uploaded to the cloud for compliance and analysis. Additionally, the PMS enhances the treatment experience by enabling clinical teams to monitor patient progress, analyze adherence to treatment protocols, and make real-time adjustments as necessary.
Future Directions
Nexalin's virtual clinic also includes a built-in telemedicine feature, facilitating direct communication between patients and the Brain-Health clinical team. This ensures personalized care and support throughout the treatment process, marking a significant advancement in the application of technology to mental health treatment.
This development represents a pivotal moment in the evolution of clinical trials and patient care, leveraging technology to make treatments more accessible and effective for individuals suffering from mental health conditions.
